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Peripheral T lymphocytes can be classified into two groups: naive and memory T cells. The focus of this study
was to examine the duration of T-cell memory in humans. Vaccinia virus replicates in the cytoplasm of infected
cells and is not thought to persist or become latent after the acute phase of infection. We identified long-lived
vaccinia virus-specific memory cytotoxic T cells in adults who had been immunized against smallpox as
children. Initially, we detected vaccinia virus-specific T cells in peripheral blood mononuclear cells while
screening for human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV-1-seropositive
subjects. These individuals had not had contact with vaccinia virus since their primary immunization in early
childhood. Several vaccinia virus-specific CD41 T-cell clones were derived from these donors and character-
ized. Healthy, HIV-1-seronegative donors who had been immunized against smallpox many (35 to 50) years
earlier were also screened for vaccinia virus-specific T-cell immunity. We found significant CD81 and CD41
cytotoxic T-cell responses to vaccinia virus after in vitro stimulation, indicating that these memory cells are
maintained in vivo for many years. The peripheral blood mononuclear cells of young adults with no history of
immunization against smallpox did not develop vaccinia virus-specific T-cell responses after in vitro stimu-
lation. Precursor frequency analysis of the vaccinia virus-specific memory CD41 T cells from a donor immu-
nized with vaccinia virus 35 years earlier revealed a frequency of 1 in 65,920 CD41 T cells. We concluded that
specific vaccinia virus T-cell immunity can persist for up to 50 years after immunization against smallpox in
childhood in the presumed absence of exposure to vaccinia virus.
The ability of a T cell to recognize a specific peptide epitope
in the context of a major histocompatibility complex molecule
on the surface of virus-infected cells is provided by its T-cell
receptor (15, 16). The interaction between the T-cell receptor
and the antigen-major histocompatibility complex triggers pro-
liferation and clonal expansion of specific T cells (15, 16). The
proliferative T-cell response continues during viral infections
until the cells expressing the viral epitopes are eliminated or
the virus becomes latent within cells and is no longer detect-
able by T cells. Some of the progeny of the antigen-responsive
T cells develop into antigen-specific memory T cells. This sub-
population of T cells is maintained within the host and pro-
vides immune surveillance. In the event of reactivation of la-
tent virus and expression of viral antigens, or subsequent
natural reexposure to the virus, specific memory T cells be-
come activated and clonally expand with greater magnitude
than during the initial response. It is generally accepted that
specific immune T-cell memory persists after an encounter
with an antigen and may help to protect the immune host
against subsequent exposure to that pathogen. The underlying
mechanisms which contribute to immunological T-cell memory
are poorly understood and have only recently received much
attention (11, 14, 17, 20, 22).
Vigorous and long-lasting protective immune responses
have long been associated with smallpox vaccination. After a
single immunization with vaccinia virus, virus-specific CD41
and CD81 cytotoxic T lymphocytes (CTL) are generated, as
evidenced by in vitro restimulation of memory T cells (7, 19).
Specific immunity is believed to be maintained for many years,
and booster immunizations are recommended every 10 years
for those at risk for infection. Because of the decreased risk of
smallpox infection and side effects of vaccination, vaccinia vi-
rus has not been generally used since routine vaccinations were
discontinued over 20 years ago. Laboratory workers using vac-
cinia virus and some members of the military continue to be
vaccinated. Vaccinia virus does not cause persistent or latent
infections, and therefore repeated endogenous antigenic stim-
ulation is not thought to occur (5). These characteristics of
vaccination against smallpox led us to investigate the longevity
of vaccinia virus-specific memory responses in humans.
Peripheral blood mononuclear cells (PBMC) of human im-
munodeficiency virus type 1 (HIV-1)-seropositive donors ex-
hibit vaccinia virus-specific cytotoxic activity against autolo-
gous B-LCL cells expressing vaccinia antigen. Cryopreserved
PBMC from 22 asymptomatic HIV-1-seropositive donors and
8 HIV-1-seronegative, healthy donors were tested directly in a
51Cr release assay as previously described for HIV-1 envelope
antigen-specific cytotoxicity by using autologous B-LCL target
cells that were either uninfected or infected with vaccinia virus
or the recombinant V/gp160 (4, 18). We detected significant
HIV-1 envelope antigen-specific cytotoxicity in the PBMC of 2
(9%) of the HIV-1-seropositive donors tested (data not
shown), but significant lysis of target cells expressing vaccinia
virus antigens was observed using the PBMC of 6 (27%) of the
HIV-1-seropositive donors, as shown in Table 1. K562 cells
were used as target cells to measure natural killer cell activity.
Establishment of vaccinia virus-specific CD41 CTL lines.
Several cell lines were obtained that specifically lysed vaccinia
virus-infected target cells after stimulation of isolated PBMC
with g-irradiated allogeneic PBMC, anti-CD3 monoclonal an-
tibody 12F6 (0.1 mg/ml), kindly supplied by J. Wong as previ-
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ously described ([28]), and recombinant human interleukin-2.
These cell lines were expanded and subcloned by limiting di-
lution at 0.3, 1, or 3 cells per well. We isolated vaccinia virus-
specific cytotoxic T-cell clones from each of three HIV-1-se-
ropositive donors (Table 2). These cell lines lysed autologous
target cells infected with vaccinia virus, and the lysis of K562
cells was low. Phenotypic analysis of these CTL lines revealed
that they were all CD31 CD41 CD82 Leu112.
Demonstration of long-lived vaccinia virus-specific CD81
CTL responses. Presumably, the HIV-1-seropositive donors
from whom the CD41 clones were generated had not been
exposed to vaccinia virus since childhood vaccination, because
the donors were over 30 years of age, had not served in the
military, and had not been vaccinated since early in childhood.
To determine whether vaccinia virus-specific CTL precursors
are maintained in the peripheral blood of individuals for long
periods of time after immunization in early childhood, two
healthy HIV-1 antibody-negative donors, VA15 and VA16,
were identified who were known to have been immunized as
children with vaccinia virus 35 and 50 years earlier, respec-
tively. These donors stated that they had no subsequent expo-
sure to vaccinia virus or to any other poxvirus. We stimulated
these two donors’ PBMC with live vaccinia virus in vitro in an
attempt to detect vaccinia virus-specific memory CD81 CTL
because we had only isolated CD41 major histocompatibility
complex class II-restricted CTL from the HIV-1-seropositive
donors by using anti-CD3 antibody and interleukin-2 stimula-
tions. This method of stimulation with live vaccinia virus had
been used earlier to successfully generate vaccinia virus-spe-
cific CD81 major histocompatibility complex class I-restricted
CTL in vitro (7).
Donor PBMC were stimulated in vitro with live vaccinia
virus, which induced a modest level of vaccinia virus-specific
proliferation, and the cultures were restimulated with anti-
CD3 antibody on day 7. On day 14, the cultures were restim-
ulated with live vaccinia virus and assayed on day 21 for cyto-
toxic activity. The bulk cultured cells derived from donors
VA15 and VA16 lysed vaccinia virus-infected autologous B-
LCL cells at levels of 50.8 and 44.2%, respectively, at an ef-
fector-target cell ratio of 50:1 (Table 3). Incubation of effector
cells with anti-CD31 or anti-CD81 specific monoclonal anti-
bodies in the presence of complement reduced the levels of
lysis significantly, indicating that CD81 CTL were the major
effector cells in this virus-stimulated population. There was
some decrease in the level of lysis after treatment with either
anti-CD41 antibodies and complement or anti-CD16 antibod-
ies and complement, suggesting a contribution by vaccinia vi-
rus-specific CD41 CTL and NK cells (Table 3).
To confirm that the vaccinia virus-specific CTL activity ob-
served in these cultures was not a result of primary in vitro
stimulation, the PBMC of two healthy, young adult donors who
had no history of immunization with vaccinia virus were used
as controls. The PBMC from these donors, VA21 and VA23,
were stimulated in a fashion identical to that used for the
PBMC of donors VA15 and VA16, were assayed on day 21 for
vaccinia virus-specific CTL activity, and had none (Table 3).
Frequency analysis of vaccinia virus-specific CTL memory
cells. As described above, the PBMC isolated from donor
VA15, who had been immunized with vaccinia virus more than
35 years ago, exhibited vaccinia virus-specific CTL activity after
stimulation in vitro. We wanted to determine the frequency of
vaccinia virus-specific memory T cells within the PBMC of this
donor. We assumed that the precursor frequency of vaccinia
virus-specific CTL would be low, so preliminary experiments
were performed to ensure that we could detect a positive
response. Sorting of donor PBMC by fluorescence-activated
cell sorter analysis yielded a relatively pure population of
CD41 T cells to assay for vaccinia virus-specific memory T
cells. Microcultures were initiated under limiting-dilution con-
ditions with 5,000 to 60,000 sorted CD41 T cells per well in 24
replicate wells. Each microculture received 2 3 105 g-irradi-
ated autologous PBMC in 200 ml of RPMI 1640 medium sup-
plemented with 20% fetal calf serum, 40 U of interleukin-2 per
ml, and vaccinia virus antigen. Vaccinia virus antigen was pre-
pared by infecting a confluent monolayer of CV-1 cells with
virus at a multiplicity of infection of 10. After 24 h of incuba-
tion, when the cytopathic effect was extensive, the cells were
harvested by scraping. After a freeze-thaw cycle, sonication
was performed and the cell-virus extract was boiled for 10 min
to inactivate any residual infectious virus before use. Gener-
ally, a confluent monolayer of vaccinia virus-infected CV-1
cells in a 75-cm2 tissue culture flask (approximately 12 3 106
cells) would yield 2 ml of cell-virus extract. At 3-day intervals,
one-half of the culture medium was removed and replaced with
TABLE 1. Vaccinia virus-specific cytotoxic activity in PBMC of
asymptomatic HIV-1-seropositive donorsa
Donor
no.
% Specific lysis of target cells
Uninfected
B-LCL
cells
Vaccinia virus-
infected
B-LCL cells
V/gp160-
infected
B-LCL cells
Uninfected
K562
cells
2 17.2 29.8 23.8 1.8
11 8.9 31.8 29.0 1.7
12 10.1 25.9 18.4 2.3
13 2.8 13.5 15.4 2.1
26 7.0 17.4 13.1 2.5
27 2.3 17.8 15.4 3.3
a Unstimulated PBMC were tested directly in a CTL assay. Cytotoxicity was
determined in a 6-h 51Cr release assay effector-target cell at an ratio of 50:1. 51Cr
release was calculated by the formula 1003 (mean experimental release2mean
spontaneous release)/(mean total release 2 mean spontaneous release). The
results of an assay were excluded if the mean level of spontaneous release was
.30%.
TABLE 2. Lysis of vaccinia virus-infected target cells by T-cell clones from HIV-1-seropositive donorsa
Donor
no.
Clone
no.
% Specific lysis of target cells
Uninfected
B-LCL cells
Vaccinia virus-infected
B-LCL cells
V/gag-infected
B-LCL cells
V/pol-infected
B-LCL cells
V/gp160-infected
B-LCL cells
Uninfected
K562 cells
11 214 0 71.8 62.8 64.8 73.5 10.4
2 140 3.1 27.7 29.6 29.3 12.6 9.8
12 109 11.4 32.8 26.5 NTb 18.5 3.3
a Cytotoxicity was determined in a 5-h 51Cr release assay at an effector-target cell ratio of 4:1. Percent specific 51Cr release was calculated as described in Table 1,
footnote a.
b NT, not tested.
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fresh medium without vaccinia virus antigen as described
above. On day 10, each well was split and cells were assayed for
cytotoxicity on autologous uninfected B-LCL cells or B-LCL
cells infected with vaccinia virus. Individual wells were consid-
ered positive if the calculated specific lysis of the virus-infected
target cells was greater than 3 standard deviations above the
mean levels of lysis calculated from negative wells. Precursor
frequencies were calculated by using x2 analysis as described by
Taswell (27), by using a computer program kindly provided by
Richard Miller (University of Michigan, Ann Arbor). Analysis
of the precursor frequency of CD41 vaccinia virus-specific
memory T cells resulted in a calculated frequency of 1 in
65,920 sorted CD41 T cells (95% confidence interval, 48,731 to
101,844 cells) or 3 in 106 PBMC (Fig. 1). Three experiments
were performed on the sorted CD41 T cells, and the calculated
frequencies for each experiment were consistent, differing by
less than 2%. This calculated frequency is lower than the re-
ported precursor frequencies for varicella-zoster virus-, HIV-
1-, and cytomegalovirus-specific T cells (3, 12, 13), but those
viruses cause persistent and/or latent infections, unlike vac-
cinia virus.
The long-lived T-cell memory responses we observed are
striking; however, a recent study suggested that memory T-cell
responses to vaccinia virus may be long lasting. In a random-
ized phase 1 trial reported by Cooney et al., 35 healthy, HIV-
1-seronegative, young adult males, 31 of whom had a history of
smallpox immunization and 4 of whom were vaccinia virus
naive, were immunized with a recombinant vaccinia virus vac-
cine expressing the gp160 envelope gene of HIV-1 (6). Indi-
viduals who had been immunized as young children with vac-
cinia virus had poor immune responses to the HIV-1 gp160
antigen compared with those who had no previous exposure to
vaccinia virus. The results from this trial suggested that long-
lasting immunity to vaccinia virus limited replication of the
recombinant vaccinia virus used for immunization (6). The
observations made during that study and data reported re-
cently on the use of vaccinia virus recombinants expressing
herpes simplex virus gene products in mice (8, 24) are consis-
tent with our finding that vaccinia virus-specific memory T-cell
responses are long lasting and may persist for life.
The results from the complement depletion assay using
bulk-cultured cells demonstrated that CD81 memory CTL ac-
tivity was dominant in short-term virus stimulated bulk cul-
tures. We expected that the precursor frequency of the CD81
FIG. 1. Frequency of vaccinia virus-specific lytic effectors among sorted
CD41 lymphocytes. Sorted CD41 T cells were stimulated with vaccinia virus
antigen. Lytic activities were measured in a CTL assay on day 10. The frequency
of vaccinia virus-specific CD41 CTL in donor VA15 was calculated as 1 in 65,920
CD41 T cells.
TABLE 3. Characterization of bulk culture cytotoxicity activity
Donor (day) and treatment
% specific 51Cr release from target cellsa
Uninfected B-LCL cells Vaccinia virus-infected B-LCL cells Uninfected K562 cells
VA15 (21)
Complement 20.2 50.8 23.1
Anti-CD41 antibodies, complement 20.3 32.9 14.7
Anti-CD81 antibodies, complement 23.3 25.5 9.8
Anti-CD31 antibodies, complement 23.4 25.1 2.7
Anti-CD161 antibodies, complement 3.8 37.4 13.0
VA16 (21)
Complement 3.3 44.2 35.3
Anti-CD41 antibodies, complement 0.0 36.9 27.3
Anti-CD81 antibodies, complement 1.7 3.4 19.0
Anti-CD31 antibodies, complement 21.3 20.2 15.7
Anti-CD161 antibodies, complement 2.3 36.2 25.9
VA21 (21)
Complement 21.9 23.5 0.3
Anti-CD31 antibodies, complement 21.1 24.9 1.1
Anti-CD161 antibodies, complement 22.8 22.7 0.4
VA23 (21)
Complement 3.2 7.2 20.1
Anti-CD31 antibodies, complement 0.6 3.3 20.7
Anti-CD161 antibodies, complement 3.6 2.3 20.2
a Effector-target cell ratio, 50:1.
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memory T-cell population would be greater than that observed
for the CD41 T cells; however, we found it difficult to deter-
mine the precursor frequency of CD81 memory T cells. The
number of CD81 cells isolated by fluorescence-activated cell
sorter analysis was only one-third of the number of CD41 T
cells, and our culture conditions with live virus may not have
been optimal for detection of relatively low numbers of vac-
cinia virus-specific CD81 T cells.
The underlying mechanisms which contribute to immuno-
logical memory are poorly understood and have only recently
received much attention. The major question with respect to
persistent immunological T-cell memory is: how is it main-
tained in vivo? There is controversy about whether the main-
tenance of memory T cells requires periodic interaction with
antigen-presenting cells expressing the relevant peptide (11,
22) or whether T-cell ‘‘memory’’ might be maintained in the
absence of specific antigen stimulation (17, 20). Oehen et al.
reported that adoptive transfer of immune spleen cells into
syngeneic recipient mice required the presence of viral antigen
for maintenance of the antiviral protective capacity of the
transferred cells (22). Gray and Matzinger reported similar
results (11). Other reports have challenged those findings (17,
20). Lau et al. used adoptive-transfer experiments in the lym-
phocytic choriomeningitis virus mouse model and reported
that memory CD81 CTL persist and retain the memory phe-
notype indefinitely in the apparent absence of priming antigen,
and these CTL apparently protected mice against virus chal-
lenge for up to 2 years (17). Mullbacher utilized a similar
approach in a mouse model of influenza virus and also con-
cluded that CTL memory is long-lived in the apparent absence
of antigen (20). Our results obtained with PBMC of adult
humans following immunization with vaccinia virus in early
childhood also suggest that persistence of antigen is not re-
quired for long-term maintenance of T-cell memory. Although
there is no evidence for the persistence of vaccinia virus or
antigens in vivo, dendritic cells may sequester antigen for pe-
riods of time, making it available for persistent stimulation of
the immune system (10).
If antigen persistence is not required, what other mecha-
nisms contribute to long-lived, specific T-cell memory? One
mechanism that has been suggested is immunological cross-
reactivity between viruses (2, 21, 25). Selin et al. used percursor
frequency analyses to study virus cross-reactive T-cell re-
sponses in mouse models and postulated that exposure to one
virus might provide a boost in immunity to an unrelated virus
(25). They could not rule out the possibility of enhanced non-
specific stimulation by lymphokines generated during the im-
mune response to the heterologous virus, but their results tend
to support the cross-reactivity hypothesis. In the absence of
significant homology among unrelated viruses, they suggested
that the observed T-cell cross reactivity may be due to cross-
reactive epitopes possessing major amino acid differences but
having discrete critical residues in common (25). This hypoth-
esis may be reasonable in light of what is known about the
phenotype of memory T cells (1, 9). When T cells acquire a
memory phenotype, they upregulate the expression of several
surface adhesion molecules in addition to the interleukin-2
receptor and become more sensitive to stimulation by a low-
affinity, T-cell-specific peptide (21, 25). This ‘‘promiscuous’’
behavior may allow a memory T cell to become activated
through an interaction of its T-cell receptor with an antigen-
presenting cell presenting a peptide epitope from a virus un-
related to the virus that induced the original immune response.
Shimojo et al. characterized a T-cell line generated against an
influenza virus-encoded peptide which specifically recognized
a dissimilar rotavirus-derived peptide (26), which supports this
hypothesis. There is an increasing number of examples of im-
munological cross reactivity between proteins of infectious or-
ganisms and human proteins (23), and this molecular mimicry
at the peptide level may play a role in T-cell cross reactivity in
vivo. The interaction of T cells with antigen-presenting cells
expressing self peptides which mimic peptide epitopes of in-
fectious agents may also stimulate their propagation. Thus,
memory T cells may be promiscuous in their ability to recog-
nize various peptides and may be stimulated in a cross-reactive
fashion.
The data presented here are perhaps the first clear evidence
that virus-specific T-cell memory can persist for up to 50 years
in humans in the presumed absence of antigen. We believe that
human subjects with prior exposure to vaccinia virus years
earlier provide an excellent model for the study of human
T-cell memory. Further elucidation of the underlying mecha-
nisms which contribute to the maintenance of T-cell memory
will have an impact on our understanding of the basis of im-
munological memory and on the design of vaccines.
We thank Ichiro Kurane for helpful discussions.
This work was supported by NIH grant AI07272 and DAMD grant
17-94-C-4063.
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